GPI launches oncology-specific value-based pricing methodology

01 November 2024

Recent advancements in cancer research have led to groundbreaking innovation in oncology therapies, significantly enhancing treatment outcomes and survival rates. However, these developments come with some key challenges, including high costs and complex regulatory & reimbursement pathways that can block access. Strong, effective market access and pricing strategies are crucial to overcome these obstacles, ensuring that new treatments reach cancer patients quickly and efficiently.

We understand the current market access and pricing challenges faced when positioning an asset within an oncology indication

There are:

• Different payer perspectives of value across markets, including variations on relevance of clinical trial endpoints

• Price pressures from government and payers in a crowded market, including policies affecting combination therapies

• Rapid changes to market and intense competition

• Time constraints to sufficiently understand oncology landscape and inform launch strategy

• Many sources require review to understand oncology landscape, particularly where a product can have multiple indications

• Uncertainties on the impact of new legislation affecting oncology products

• Limited data to determine price potential early on

We know that asset success goes beyond clinical data and relies upon quick and early consideration of the broader landscape

As part of market access strategy for an oncology asset, it is important to:

• Navigate payer expectations. This helps to identify opportunities for evidence generation, anticipate focus and risk areas of appraisal and refine strategy

• Monitor the competitive landscape. This helps to spot new opportunities, identify areas of risk and target an unmet need for achieving long-term success

• Increase efficient decision-making. This helps to make quick strategic evidence-based decisions, reduce resources required for research and lower early pricing & market access costs

GPI’s oncology-specific value-based pricing methodology is an evidence-driven approach that rapidly considers payer value and market landscape to help position an oncology asset

It incorporates 4 key elements:

1. Analogue and comparator selection: easily identify and select analogues/comparators relevant to your asset
2. Multi-scenario TPP assessment: quickly assess asset TPP across various markets and numerous scenarios with our payer validated criteria
3. Value-based price forecast: estimate price potential based on market-specific payer perception of value
4. Integrate internal pricing assumptions: incorporate known internal pricing data, including confidential discounting and rebates

It offers for a fast and cost-effective way to gain competitive intelligence, payer insights and price forecasts for your asset.

GPI’s value-based pricing methodology can be applied in multiple oncology scenarios, including:

• Determining the optimal indication of an asset currently in clinical development across multiple indications

• Identifying the gaps for evidence generation activities for an asset entering a crowded market in oncology

• Estimating the price potential of an asset when there are no direct competitors i.e. no clear treatment options except palliative care

GPI’s value-based pricing methodology can be tailored to suit your needs in oncology and beyond

We combine our data, technology and professional services to tailor our solutions; however big or small! GPI’s value-based pricing methodology can be integrated within wider market access and pricing activities to support the launch of an asset, including, but not limited to:

• Reimbursement potential assessment

• TPP assessment and evidence optimisation

• Competitor intelligence & tracking

• Payer validation

• Data ingestion into internal pricing tool

• Launch sequencing

• Indication expansion analysis